Psychedelic medicines company Compass Pathways (Nasdaq: CMPS) was trading 46% lower midday Monday.
The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, the first of two Phase III trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).
The primary endpoint is the difference in change from baseline in the Montgomery-Åsberg depression rating scale (MADRS) scores between the active treatment group and the placebo group at week six.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze